TIDMRENX
RNS Number : 7276R
Renalytix PLC
09 November 2021
Renalytix plc
("Renalytix" or the "Company")
St. Joseph's Health and Renalytix Partner to Advance Value-Based
Kidney Health
in New York
Partnership expands doctor and patient access to advanced
prognosis and coordinated care management of early-stage diabetic
kidney disease
NEW YORK, November 9, 2021 - St. Joseph's Health and Renalytix
plc (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to
implement an advanced clinical care model designed to improve
kidney health in patients with type 2 diabetes and early-stage
chronic kidney disease. The Renalytix KidneyIntelX(TM) platform
will be integrated with St. Joseph's Health care management to help
prevent patients with diabetes and early-stage kidney disease from
unnecessarily progressing to significant disease and/or kidney
failure. KidneyIntelX is designed to enable primary care and
specialist physicians to easily understand risk and implement St.
Joseph's Health medication management, nutrition and education
intervention protocols on a timely basis.
St. Joseph's Health is part of Trinity Health, one of the
largest multi-institutional Catholic health care delivery systems
in the U.S., serving diverse communities that include more than 30
million people across 25 states. KidneyIntelX test risk assessment
will be available through St. Joseph's Hospital's electronic health
record (EHR) system, providing access to primary care physicians,
endocrinologists, nephrologists, and care teams.
"A challenge in healthcare is that approximately 35 million
people have been diagnosed with diabetes and 20% of those patients
with diabetes will progress to kidney failure. The Renalytix IVD
test is the first tool to enable early-stage progression risk
assessment in early diabetic kidney disease," said Paul Fiacco, MD,
Medical Director, Trinity Health Integrated Care ACO and President
of CNY AIM (a clinically integrated network affiliated with St.
Joseph's Health). "This risk assessment allows primary care
clinicians to provide early intervention to their identified
high-risk patients to prevent future disease progression to kidney
failure. This partnership with Renalytix is motivated by our common
desire to expand our value proposition to larger populations and
further strengthen our population health management
capabilities."
"St. Joseph's Health is involved in several different
value-based, accountable care agreements, including, but not
limited to, the Medicare Shared Savings Program and the Excellus
Blue Cross Blue Shield's Accountable Cost Quality Agreement," said
Mike Endries, Executive Director, CNY AIM ( www.cnyaim.org ).
"These accountable care agreements encourage our providers to
employ population health management initiatives and to engage with
patients in the early identification and treatment of chronic
disease. The partnership with Renalytix furthers our efforts to
create a physician-led, people-centered health care system that
improves the health care outcomes of our patients, specifically
those who may be at risk for early-stage CKD."
"St. Joseph's Health shares our forward-thinking,
patient-centric approach to changing the standard of care in kidney
health. St. Joseph's Health's early-stage chronic kidney disease
care model, powered by KidneyIntelX, is expected to drive improved
clinical and cost outcomes to make healthier kidneys both
attainable and sustainable,
" said Christine Loftsgaarden, VP, Commercial Partnerships at Renalytix.
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker Tel: 020 7710 7600
)
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391
303
CapComm Partners Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and one out of two people with very low kidney
function who are not on dialysis do not know they have CKD.(1)
Kidney disease is referred to as a "silent killer" because it often
has no symptoms and can go undetected until a very advanced stage.
Each year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
About St. Joseph's
St. Joseph's Health is a regional non-profit health care system
based in Syracuse, NY. St. Joseph's has been an innovative leader
in health care since our founding in 1869 as the first hospital
open to the public in the city of Syracuse. Offering primary,
specialty and home care, a Magnet-recognized hospital, and
collaboration with community partners, St. Joseph's Health advances
the well-being of the communities we serve through an expanding
range of services to ensure our patients achieve optimum long-term
health. St. Joseph's is one of America's 50 Best Hospitals for
Cardiac Surgery and one of America's 100 Best for Spine Surgery and
Coronary Intervention according to Healthgrades. It is ranked by
Consumer Reports among the top 15 heart surgery centers in the
country, a designated Stroke Center and a U.S. News "Best Regional
Hospital." St. Joseph's Health is affiliated with St. Joseph's
Physicians , and is a member of Trinity Health . For more
information, visit www.sjhsyr.org/legacy .
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and
leader in the new field of bioprognosis(TM) for kidney health. The
company has engineered a new solution that successfully enables
early-stage chronic kidney disease, progression risk assessment.
The Company's lead product, KidneyIntelX, has been granted
Breakthrough Designation by the U.S. Food and Drug Administration
and is designed to help make significant improvements in kidney
disease prognosis, transplant management, clinical care, patient
stratification for drug clinical trials, and drug target discovery
(visit www.kidneyintelx.com ). For more information, visit
www.renalytix.com .
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables
early-stage diabetic kidney diseases (DKD) progression risk
assessment by combining diverse data inputs, including validated
blood-based biomarkers, inherited genetics, and personalized
patient data from electronic health record, or EHR, systems, and
employs a proprietary algorithm to generate a unique patient risk
score. This patient risk score enables prediction of progressive
kidney function decline in CKD, allowing physicians and healthcare
systems to optimize the allocation of treatments and clinical
resources to patients at highest risk.
Sources
1
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Examples of these forward-looking statements
include statements concerning: the potential benefits, including
economic savings, of KidneyIntelX, the potential for KidneyIntelX
to receive regulatory approval from the FDA, the commercial
prospects of KidneyIntelX, if approved, including whether
KidneyIntelX will be successfully adopted by physicians and
distributed and marketed, our expectations regarding reimbursement
decisions and the ability of KidneyIntelX to curtail costs of
chronic and end-stage kidney disease, optimize care delivery and
improve patient outcomes. Words such as "anticipates," "believes,"
"estimates," "expects," "intends," "plans," "seeks," and similar
expressions are intended to identify forward-looking statements. We
may not actually achieve the plans and objectives disclosed in the
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Any forward-looking statements
are based on management's current views and assumptions and involve
risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
among others: that KidneyIntelX is based on novel artificial
intelligence technologies that are rapidly evolving and potential
acceptance, utility and clinical practice remains uncertain; we
have only recently commercially launched KidneyIntelX; and risks
relating to the impact on our business of the COVID-19 pandemic or
similar public health crises. These and other risks are described
more fully in our filings with the Securities and Exchange
Commission (SEC), including the "Risk Factors" section of our
annual report on Form 20-F filed with the SEC on October 21, 2021,
and other filings we make with the SEC from time to time. All
information in this press release is as of the date of the release,
and we undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEADFPEELFFAA
(END) Dow Jones Newswires
November 09, 2021 02:00 ET (07:00 GMT)
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024